Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 180 CLL: pirtobrutinib plus epcoritamab for relapsed/refractory CLL or SLL
NL-OMON61385Phase 2Not yet recruiting
- Sponsor
- HOVON
- Start
- Oct 2026
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirtobrutinib and epcoritamab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by HOVON. Primary endpoints: Safety in safety run-in and Progression-free survival at 24 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
pirtobrutinibepcoritamab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON61385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61385.